Genomics is the field of study concerned with the complete set of an organism’s genetic material — its genome — and how that genetic information is structured, expressed, and regulated. Where genetics traditionally focused on the function of individual genes, genomics takes a systems-level view, examining how the entire genome operates, interacts, and produces the traits and biological functions of an organism. For biopharma, genomics is foundational: it underlies drug discovery, clinical diagnostics, and gene therapy alike, and a working understanding of its core concepts is necessary to follow how modern therapeutics are actually developed.

What Is the Relationship Between DNA, Genes, and Chromosomes?

DNA, or deoxyribonucleic acid, is the molecule that encodes genetic information using a four-letter chemical alphabet — adenine, thymine, guanine, and cytosine. A gene is a specific sequence of DNA that contains the instructions for producing a particular protein or functional RNA molecule. Chromosomes are the structures that organize and package an organism’s DNA — humans carry 23 pairs of chromosomes, containing an estimated 20,000 to 25,000 genes in total, though the precise count remains an active area of ongoing research as genomic annotation continues to improve.

The relationship among these three levels is hierarchical: chromosomes contain genes, genes are made of DNA, and DNA’s sequence determines what proteins a cell can produce. Understanding genomics means understanding how information flows through this hierarchy — and, critically, how that flow can be disrupted, modified, or therapeutically targeted.

What Are Single Nucleotide Polymorphisms, and Why Do They Matter?

A single nucleotide polymorphism, or SNP, occurs when a single nucleotide — one letter in the DNA sequence — is naturally substituted for another at a specific position in the genome. SNPs are the most common type of genetic variation between individuals, and they are central to a substantial portion of modern genomic research, because they help explain why people respond differently to the same drug, why some individuals are more susceptible to certain diseases than others, and why a treatment effective for one patient population may be ineffective or even harmful for another.

Identifying and understanding relevant SNPs is a core part of pharmacogenomics — the study of how genetic variation affects an individual’s response to drugs — which has become an increasingly important consideration in both clinical trial design and, in some therapeutic areas, treatment selection for individual patients.

How Does Gene Expression Work?

Having a gene present in the genome does not mean that gene is actively producing protein at any given moment. Gene expression is the process by which the information encoded in a gene is used to synthesize a functional product, typically a protein. This process involves transcription, in which the DNA sequence of a gene is copied into a messenger RNA molecule, followed by translation, in which that messenger RNA is used as a template to assemble a chain of amino acids into a protein.

Gene expression is tightly regulated — cells in different tissues express different subsets of genes despite containing identical DNA, which is part of what allows a liver cell and a neuron, both carrying the same genome, to perform entirely different biological functions. Understanding the regulatory mechanisms that control gene expression is central to both basic biological research and to the development of therapies designed to turn specific genes on or off.

What Genomic Technologies Have Transformed Modern Biopharma?

Several technological advances have made genomics commercially and clinically actionable in ways that weren’t possible even two decades ago. Next-generation sequencing dramatically reduced the cost and time required to sequence a genome, making large-scale genomic analysis routine in both research and, increasingly, clinical settings. Gene editing technologies — most notably CRISPR-Cas9, alongside earlier tools like zinc finger nucleases and TALENs — gave researchers the ability to make precise, targeted modifications to specific genomic sequences, enabling both basic research into gene function and the development of therapies that directly correct or modify disease-causing genetic sequences.

These technologies, combined, have shifted genomics from a primarily descriptive science — characterizing what genetic variation exists — toward an interventional one, capable of directly modifying the genome for therapeutic purposes. This shift is what underlies the entire cell and gene therapy field as it exists today.

How Does Genomics Relate to Epigenetics and Other Adjacent Fields?

Genomics is often discussed alongside related but distinct fields that examine different layers of biological information. Epigenetics studies changes in gene expression that occur without altering the underlying DNA sequence itself — chemical modifications that influence which genes are turned on or off in a given cell, often in response to environmental factors. Proteomics studies the full set of proteins an organism produces, which is influenced by but not identical to its genomic sequence, since gene expression, post-translational modification, and other factors all shape which proteins are actually present and active at a given time. Each of these fields adds a layer of biological information that genomics alone does not capture, and increasingly, biopharma research integrates findings across these disciplines rather than treating them as separate areas of study.

Why Does Genomics Matter for Drug Discovery and Clinical Diagnostics?

In drug discovery, genomics helps identify which genes and proteins are involved in a given disease process, narrowing the universe of potential therapeutic targets to those with strong genetic evidence of disease relevance — a substantially more efficient starting point than earlier, less targeted approaches to drug discovery. In clinical diagnostics, genomic technologies underlie an expanding category of tests that identify disease risk, confirm diagnoses, or guide treatment selection based on a patient’s specific genomic profile, an approach often described as precision or personalized medicine.

Understanding genomics, at this level of depth, is what allows an executive working anywhere in the biopharma value chain — not just in R&D — to follow how a therapeutic candidate was identified, why a particular patient population was selected for a clinical trial, or what a companion diagnostic is actually measuring when it determines whether a patient is eligible for a genomically targeted therapy.